Navigation Links
Fuzeon and MK-0518 Combo Holds Promise For HIV

Swiss Pharmaceutical Company Roche Holding Ltd. and biotech drug maker Trimeris Inc. announced the potential benefits of their HIV drug Fuzeon// along with Merck & Co.'s drug MK-0518, still undergoing clinical trials, is capable of cutting the levels of the virus to incredible levels, in a majority of study subjects.

A study to test the efficacy of the drug, sponsored by Merck, found that 90 percent to 95 percent of a section of patients who were administered Fuzeon for the first time along with MK-0518, showed incredible reduction in HIV, as against the 60 percent to 70 percent of the section who were administered MK-0518 alone.

Roche and Trimeris are ecstatic with the path breaking success rates, evident during clinical trials of HIV patients who have been suffering the drug-resistant virus. Following this announcement, shares of Trimeris showed a heady jump to 83 cents on NASDAQ. Shares of Merck plummeted 18 cents to $41.76 on the New York Stock Exchange.

Page: 1

Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
11. Germ - Chemo Combo Fights Cancer
Post Your Comments:

(Date:12/1/2015)... , ... December 01, 2015 , ... According to an ... groups has filed a discrimination claim against the U.S. Department of Health and Human ... Affordable Care Act (ACA) plans are breaking the clause in the law prohibiting the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... ... , ... Growth in medical payments per workers’ compensation claim in Louisiana slowed ... nonhospital care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... medical payments per claim with more than seven days of lost time continued to ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced ... Bridge Business Awards under the New Products and Services category for its innovative ... sample management software that helps labs organize data and track samples with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
Breaking Medicine Technology: